Amgen looks for Five Prime payback
A key pivotal study of bemarituzumab will read out shortly.
Yet more conjugates enter the clinic
Recent phase 1 entrants include a ROR1 ADC and a mystery Kelun project.
ASCO-GU – another strike against Cabometyx
A triplet did worse than control in first-line kidney cancer.
Boehringer beats Bayer to the regulators
The FDA will rule on a low dose of zongertinib in the summer.
Chimerix's cancer transformation
US approval could mark the company's graduation to oncology.
